What is Molecule?
Molecule operates at the intersection of biotechnology and decentralized finance, providing a robust infrastructure designed to accelerate innovation within the pharmaceutical sector. By facilitating a collaborative open market, the platform enables scientists, patients, and industry stakeholders to engage in the distributed research and development of pharmaceutical intellectual property. The core value proposition lies in the Molecule protocol, which allows IP creators to exchange partial ownership of their innovations for essential liquidity and research capital. This model effectively distributes the inherent risks and costs associated with drug development, fostering a more inclusive and diverse ecosystem for bringing novel treatments to market. By reimagining the traditional R&D pipeline, Molecule is establishing itself as a critical layer in the future of life sciences infrastructure.
How much funding has Molecule raised?
Molecule has raised a total of $13M across 1 funding round:
Angel/Seed
$13M
Angel/Seed (2022): $13M with participation from Backed, Shine Capital, Speedinvest, and Northpond Ventures
Key Investors in Molecule
Backed
A human-centric seed fund that supports founders building generation-defining companies in frontier technology with a focus on long-term relationship building.
Shine Capital
An early-stage venture capital firm that partners with creative and determined entrepreneurs to build iconic, high-impact businesses.
Speedinvest
A prominent European venture capital fund with over 1 billion euros under management, specializing in pre-seed and seed-stage investments across deep tech and health bio sectors.
What's next for Molecule?
With this major enterprise-level funding, Molecule is poised to expand its operational footprint and enhance its protocol capabilities. The strategic roadmap likely involves deepening partnerships with academic institutions and biotech firms to increase the volume of IP assets on the platform. As the company matures, the focus will shift toward optimizing liquidity mechanisms and ensuring regulatory compliance across global markets. By leveraging its recent capital injection, Molecule aims to solidify its position as the primary marketplace for decentralized drug discovery, ultimately reducing the time-to-market for breakthrough therapies and creating sustainable business models for the next generation of scientific entrepreneurs.
See full Molecule company page
